



ONCOLOGY

At Lilly Oncology, we seek enabling therapeutic development platforms, breakthrough monotherapy programs and opportunities for rational combinations with our existing pipeline.

Our greatest interests lie in novel assets in the following areas:

- Immuno-oncology approaches: Therapies focused on neoantigens, T-cell redirection, novel checkpoint agents and disruptive immunotherapy targets/platforms
- Tumor metabolism pathway modulators: Agents targeting the tumor microenvironment and interplay between the microenvironment, immune system and tumor energetics
- Novel approaches targeting tumor dependencies in molecularly enriched populations
- Modulating epigenetic pathways

HAVE AN IDEA?

COLLABORATE WITH US.

▷ lilly.com/partners